Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: A multi-marker approach - The North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II)

Clinical Research in Cardiology

Volumn 96, Issue 9, 2007, Pages 604-612

  Mockel M ^a   Müller, Reinhold ^b   Vollert, Jörn O ^a   Müller, Christian ^a   Danne, Oilver ^a   Gareis, Ragnar ^c   Störk, Thomas ^c   Dietz, Rainer ^a   Koenig, Wolfgang ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b JAMES COOK UNIVERSITY   (Australia)

^c Karl Olga Krankenhaus   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Acute coronary syndrome; CART analysis; Emergency room; LP PLA2; NT proBNP; Troponin I

Indexed keywords

BIOCHEMICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; D DIMER; PHOSPHOLIPASE A2; TROPONIN I;

ACUTE CORONARY SYNDROME; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DISEASE CLASSIFICATION; DISEASE SEVERITY; ELECTROCARDIOGRAM; EMERGENCY WARD; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; IMMUNOASSAY; INCIDENCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; POINT OF CARE TESTING; PRACTICE GUIDELINE; RESUSCITATION; SENSITIVITY AND SPECIFICITY;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACUTE CORONARY SYNDROME; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TROPONIN I;

EID: 34548609185     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-007-0540-x     Document Type: Article

References (47)

1. Apple FS, Wu AHB, Mair J et al (2005) Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 51(5):810-824
2. Lindahl B, Lindback J, Jernberg T et al (2005) Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: A Fragmin and fast Revascularisation during InStability in coronary artery disease (FRISC)-II substudy. Journal of the American College of Cardiology 45(4):533-541
3. Task Force on Pulmonary Embolism ESoC (2000) Guidelines on diagnosis and management of acute pulmonary embolism. Eur Heart J 21(16):1301- 1036
4. Derhaschnig U, Laggner AN, Roggla M et al (2002) Evaluation of Coagulation Markers for Early Diagnosis of Acute Coronary Syndromes in the Emergency Room. Clin Chem 48(11):1924-1930
5. Ross R (1999) Atherosclerosis - An Inflammatory Disease. N Engl J Med 340(2):115-126
6. Pentikainen MO, Oorni K, Ala-Korpela M et al (2000) Modified LDL - trigger of atherosclerosis and inflammation in the arterial intima. Journal of Internal Medicine 247(3):359-370
7. Caslake MJ, Packard CJ (2003) Lipoprotein- associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease. Curr Opin Lipidol 14(4):347-352
8. Tselepis AD, John Chapman M (2002) Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein- associated phospholipase A2, platelet activating factor-acetylhydrolase. Atherosclerosis Supplements 3(4):57-68
9. Dada N, Kim NW, Wolfert RL (2002) Lp-PLA2: an emerging biomarker of coronary heart disease. Expert Review of Molecular Diagnostics 2(1): 17-22
10. Stafforini DM, McIntyre TM, Zimmerman GA et al (1997) Platelet-activating Factor Acetylhydrolases. J Biol Chem 272(29):17895-17898
11. Arai H, Koizumi H, Aoki J et al (2002) Platelet-activating factor acetylhydrolase (PAF-AH). J Biochem (Tokyo) 131(5):635-640
12. Stafforini DM, Elstad MR, McIntyre TM et al (1990) Human macrophages secret platelet-activating factor acetylhydrolase. J Biol Chem 265(17):9682-9687
13. Asano K, Okamoto S, Fukunaga K et al (1999) Cellular Source(s) of Platelet- Activating-Factor Acetylhydrolase Activity in Plasma. Biochemical and Biophysical Research Communications 261(2):511-514
14. Tarbet EB, Stafforini DM, Elstad MR et al (1991) Liver cells secrete the plasma form of platelet-activating factor acetylhydrolase. J Biol Chem 266(25):16667-16673
15. Hakkinen T, Luoma JS, Hiltunen MO et al (1999) Lipoprotein-Associated Phospholipase A2, Platelet-Activating Factor Acetylhydrolase, Is Expressed by Macrophages in Human and Rabbit Atherosclerotic Lesions. Arterioscler Thromb Vasc Biol 19(12):2909-2117
16. Caslake MJ, Packard CJ, Suckling KE et al (2000) Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 150(2):413-419
17. Steinbrecher UP, Pritchard PH (1989) Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase. J Lipid Res 30(3):305-315
18. Macphee CH (2001) Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target. Curr Opin Pharmacol 1(2):121-125
19. Leach CA, Hickey DM, Ife RJ et al (2001) Lipoprotein-associated PLA2 inhibition-a novel, non-lipid lowering strategy for atherosclerosis therapy. Farmaco 56(1-2):45-50
20. Oei HH, van der Meer IM, Hofman A et al (2005) Lipoprotein-Associated Phospholipase A2 Activity Is Associated With Risk of Coronary Heart Disease and Ischemic Stroke: The Rotterdam Study. Circulation 111(5):570-575
21. Packard CJ, O'Reilly DSJ, Caslake MJ et al (2000) Lipoprotein-Associated Phospholipase A2 as an Independent Predictor of Coronary Heart Disease. N Engl J Med 343(16):1148-1155
22. Ballantyne CM, Hoogeveen RC, Bang H et al (2004) Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle- Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 109(7):837-842
23. Khuseyinova N, Imhof A, Rothenbacher D et al (2005) Association between Lp-PLA2 and coronary artery disease: Focus on its relationship with lipoproteins and markers of inflammation and hemostasis. Atherosclerosis 182(1):181-188
24. Koenig W, Khuseyinova N, Lowel H et al (2004) Lipoprotein-Associated Phospholipase A2 Adds to Risk Prediction of Incident Coronary Events by C-Reactive Protein in Apparently Healthy Middle-Aged Men From the General Population: Results From the 14-Year Follow-Up of a Large Cohort From Southern Germany. Circulation 110(14):1903-1908
25. Brilakis ES, McConnell JP, Lennon RJ et al (2005) Association of lipoprotein- associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 26(2):137-144
26. Schuler J, Maier B, Behrens S et al (2006) Present treatment of acute myocardial infarction in patients over 75 years - data from the Berlin Myocardial Infarction Registry (BHIR). Clin Res Cardiol 95(7):360-367
27. Prontera C, Emdin M, Zucchelli GC et al (2004) Analytical performance and diagnostic accuracy of a fullyautomated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide. Clin Chem Lab Med 42(1):37-44
28. Crichton NJ, Hinde JP, Marchini J (1997) Models for diagnosing chest pain: is CART helpful? Stat Med 16(7):717-727
29. Möckel M, Müller R, Vollert JO et al (2005) Role of N-Terminal Pro-BType Natriuretic Peptide in Risk Stratification in Patients Presenting in the Emergency Room. Clin Chem 51(9):1624-1631
30. Kastrati A, Schomig A, Elezi S et al (1997) Predictive Factors of Restenosis After Coronary Stent Placement. Journal of the American College of Cardiology 30(6):1428-1436
31. Breiman L, Friedman JOR, Stone C (1984) Classification and regression trees. Chapman and Hall
32. Antman EM, Cohen M, Bernink PJLM et al (2000) The TIMI Risk Score for Unstable Angina/Non-ST Elevation MI: A Method for Prognostication and Therapeutic Decision Making. JAMA 284(7):835-842
33. Omland T, Persson A, Ng L et al (2002) N-Terminal Pro-B-Type Natriuretic Peptide and Long-Term Mortality in Acute Coronary Syndromes. Circulation 106(23):2913-2918
34. Mega JL, Morrow DA, de Lemos JA et al (2004) B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: An ENTIRE-TIMI- 23 substudy. Journal of the American College of Cardiology 44(2):335-339
35. Morrow DA, de Lemos JA, Blazing MA et al (2005) Prognostic Value of Serial B-Type Natriuretic Peptide Testing During Follow-up of Patients With Unstable Coronary Artery Disease. JAMA 294(22):2866-2871
36. Morrow DA, de Lemos JA, Sabatine MS et al (2003) Evaluation of B-type natriuretic peptide for risk assessment in unstable Angina/Non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICSTIMI 18. Journal of the American College of Cardiology 41(8):1264-1272
37. Weber M, Kleine C, Keil E et al (2006) Release pattern of N-terminal pro Btype natriuretic peptide (NT-proBNP) in acute coronary syndromes. Clin Res Cardiol 95(5):270-280
38. Doust JA, Glasziou PP, Pietrzak E et al (2004) A Systematic Review of the Diagnostic Accuracy of Natriuretic Peptides for Heart Failure. Arch Intern Med 164(18):1978-1984
39. Clerico A, Emdin M (2004) Diagnostic Accuracy and Prognostic Relevance of the Measurement of Cardiac Natriuretic Peptides: A Review. Clin Chem 50(1):33-50
40. Antman E, Bassand JP, Klein W et al (2000) Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction: The Joint European Society of Cardiology/American College of Cardiology Committee. Journal of the American College of Cardiology 36(3):959-969
41. Braunwald E, Antman EM, Beasley JW et al (2002) ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). Journal of the American College of Cardiology 40(7):1366-1374
42. Bertrand ME, Simoons ML, Fox KAA et al (2002) Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 23(23):1809-1840
43. Boden WE (2005) Acute Coronary Syndromes without ST-Segment Elevation - What Is the Role of Early Intervention? N Engl J Med 353(11): 1159-1161
44. Ridker PM, Hennekens CH, Buring JE et al (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342(12):836-843
45. Ridker PM, Cannon CP, Morrow D et al (2005) C-Reactive Protein Levels and Outcomes after Statin Therapy. N Engl J Med 352(1):20-28
46. Sabatine MS, Morrow DA, de Lemos JA et al (2002) Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes: Simultaneous Assessment of Troponin I, C-Reactive Protein, and B-Type Natriuretic Peptide. Circulation 105(15):1760-1763
47. O'Donoghue M, Morrow DA, Sabatine MS et al (2006) Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) Trial. Circulation 113(14):1745-1752